Randomized trial demonstrates improved overall survival with A+AVD over ABVD in advanced Hodgkin lymphoma, indicating a superior frontline treatment regimen.
Patients who received A+AVD for the treatment of stage III or IV Hodgkin's lymphoma had a survival advantage over those who received ABVD. (Funded by Takeda Development Center Americas and Seagen; ECHELON-1 ClinicalTrials.gov number, NCT01712490; EudraCT number, 2011-005450-60.).
No takes yet. Share an insight, caveat, or question.
Ansell et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: